Panel of experts: Professor Michael Mauro Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York (USA) Dr Naranie Shanmuganathan Royal Hospital and SA Pathology, Adelaide (Australia)

Program:
COVID-19 and CML - an update on the CANDID data: (Michael Mauro)

• ABL inhibition, CML and coronavirus
• Imatinib and asciminib vs. SARS-CoV-2
• Trials utilizing imatinib in COVID-19
• CML and COVID-19: Uncertainty
• The CANDID study
  • Study design
  • Geographic distribution and characteristics
  • Current treatments
  • Diagnosis and clinical history
  • COVID-19 severity
  • Impact of COVID-19 infection on CML therapy
  • Predictive factors for disease severity and survival

COVID-19 vaccines perception in CML patients (Naranie Shanmuganathan)

• Design of the vaccine perception study
• Demographics of surveyed patients
• Results from the patient perception study
  • Current TKI use
  • Sources of information re. COVID-19 vaccines
  • Patient understanding of safety and expected effectiveness
  • Patients need for more information
  • Patients willingness to get vaccinated
• Conclusion

Q&A Session